Patents by Inventor Kurt Armbrust

Kurt Armbrust has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted Imidazopyrazine Compounds as IRAK3 Binders
    Publication number: 20260234148
    Abstract: Provided herein are compounds and compositions thereof that bind to IRAK3.
    Type: Application
    Filed: July 24, 2023
    Publication date: August 13, 2026
    Applicant: Celgene Corporation
    Inventors: Farid van der Mei, Guobin Miao, Rulin Ma, Laura Akullian D'Agostino, Kurt Armbrust
  • Substituted Pyrazolyl-Pyridinyl Compounds as Ligand Directed Degraders of IRAK3
    Publication number: 20260234124
    Abstract: Provided herein are compounds and compositions thereof for modulating IRAK3. In some embodiments, the compounds and compositions are provided for treatment of cancer.
    Type: Application
    Filed: July 24, 2023
    Publication date: August 13, 2026
    Applicant: Celgene Corporation
    Inventors: Farid van der Mei, Guobin Miao, Rulin Ma, Laura Akullian D'Agostino, Kurt Armbrust
  • Substituted Imidazo-Based Compounds as Ligand Directed Degraders of IRAK3
    Publication number: 20260216347
    Abstract: Provided herein are compounds and compositions thereof for modulating IRAK3. In some embodiments, the compounds and compositions are provided for treatment of cancer.
    Type: Application
    Filed: December 20, 2023
    Publication date: July 30, 2026
    Applicant: Celgene Corporation
    Inventors: Farid van der Mei, Guobin Miao, Laura Akullian D'Agostino, Rulin Ma, Kurt Armbrust
  • Substituted Imidazopyrazine Compounds as Ligand Directed Degraders of IRAK3
    Publication number: 20260028343
    Abstract: Provided herein are compounds and compositions thereof for modulating IRAK3. In some embodiments, the compounds and compositions are provided for treatment of cancer.
    Type: Application
    Filed: July 24, 2023
    Publication date: January 29, 2026
    Applicant: Celgene Corporation
    Inventors: Farid van der Mei, Guobin Miao, Rulin Ma, Laura Akullian D'Agostino, Kurt Armbrust
  • ESTROGEN RECEPTOR ALPHA DEGRADERS AND METHODS OF USE THEREOF
    Publication number: 20250388565
    Abstract: The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for degrading ER? with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with ER?-mediated transcription regulation with the compounds and compositions of the disclosure.
    Type: Application
    Filed: June 27, 2023
    Publication date: December 25, 2025
    Inventors: Alexander M. Taylor, Kurt Armbrust, Christopher A. Lepre, Thomas H. McLean, Paul R. Fleming, Rulin MA, Erich W. Baum, Cary Griffin Fridrich, Jing He, Charles R. Heap, Jay F. Larrow, Rukundo Ntaganda
  • Thienopyridine inhibitors of RIPK2
    Patent number: 11168093
    Abstract: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Grant
    Filed: December 20, 2019
    Date of Patent: November 9, 2021
    Assignee: Celgene Corporation
    Inventors: Kurt Armbrust, Fedor Romanov Michailidis, Karin Irmgard Worm, John Michael Ellis
  • THIENOPYRIDINE INHIBITORS OF RIPK2
    Publication number: 20200199148
    Abstract: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Application
    Filed: December 20, 2019
    Publication date: June 25, 2020
    Inventors: Kurt Armbrust, Fedor Romanov Michailidis, Karin Irmgard Worm, John Michael Ellis